April 07, 2017
RealTime Dynamix™: Multiple Sclerosis US Q2
The Multiple Sclerosis (MS) market is more dynamic and complex than ever with several disease-modifying therapies (DMTs) currently available and a potential game-changer entry, in the form of Roche/Genentech’s Ocrevus (ocrelizumab), approved by the FDA on March 28, 2017. RealTime Dynamix™: Multiple Sclerosis allows marketing professionals to keep abreast and react to these market changes and provides critical information that will support their commercial strategies.
The quarterly reports include a detailed and timely look at current trends in the market, key performance metrics, brand gains and losses, key metrics for recently launched products and awareness of products in development. Additionally, an in-depth study of MS patient engagement and its impact in treatment decisions, an analysis of the effectiveness of alternative marketing channels to reach neurologists, and a DMT attribute study are incorporated in specific editions throughout the year.
About Spherix Global Insights
Spherix Global Insights is a business intelligence and market research company, specializing in renal, autoimmune, neurologic and rare disease markets. Our aim is to apply our commercial experience and unique relationships within core specialty markets to translate data into insight, enabling our clients to make smarter business decisions.